- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Report: Atrial Fibrillation Drug Market to Grow Dramatically Over Next Decade
Eliquis (apixaban) expected to be leading anticoagulant (Nov. 12)Decision Resources, a research and advisory firm, reports that the atrial fibrillation drug market will experience dramatic growth over the next decade, increasing from $2.7 billion in 2011 to $9.2 billion in 2021 in the U.S., Europe, and Japan.
The company predicts that novel oral anticoagulants developed for the prevention of stroke in atrial fibrillation patients will be the main catalysts of market growth. Eliquis (apixaban, Bristol-Myers Squibb/Pfizer) is expected to be the sales-leading anticoagulant, garnering more than $3 billion in 2021. The use of new anticoagulants will result in a steep decline in sales of warfarin — including Coumadin (Bristol-Myers Squibb) — and other vitamin K antagonists.
Xarelto (rivaroxaban, Bayer/Janssen) is expected to be the second best-selling agent, largely because of its once-daily dosing, and will reach peak-year sales of $2 billion.
The company’s findings also reveal that the absence of efficacious antiarrhythmic agents with strong safety profiles is likely to continue as the anti-anginal agent Ranexa (ranolazine, Gilead/Menarini) is the only antiarrhythmic drug forecasted to launch through 2021. Despite promising trial data, Ranexa is not expected to achieve significant market share, owing primarily to the entry of generic ranolazine in 2019.
Source: Decision Resources; November 12, 2012.Decision Resources